committee keep in mind that we cannot force foreign governments 
to comply, and that perhaps acceptance of these guidelines would 
be a more favorable target. 
Dr. McGarrity asked Mr. Lanman if Mr. Brewer's withdrawn motion 
was a reasonable starting point for the next round of publication 
in the Federal Register , and still allow for limited modification 
at the next meeting of the RAC. Mr. Lanman said there were 
several options: 
1. A decision could be made on one version to 
recommend to the Director of NIH; 
2. The Director, NIH, could be asked to publish 
alternate versions for comment; or 
3. It could be left to the Director's discretion 
to publish a version which would meet certain 
criteria, and allow the Director to provide 
the specific language. 
Dr. Gartland asked whether the sense of the committee was that 
what was voted on today go out for further comment and brought 
back to the October RAC meeting or whether the whole issue should 
go back to a working group for even further work and brought back 
in October. Dr. Korwek said there was enough dispute over what 
specific words meant and how they should be construed, and that 
there were many diverse viewpoints being dealt with, and he felt 
it should go back to the working group for eventual republication 
for comment. General agreement was voiced around the table for 
sending the proposals back to the working group. 
Dr. McGarrity thanked Dr. Cohen and the working group for their 
efforts on these topics. 
V. PROPOSED AMENDMENT OF SECTION III-B-5 OF THE NIH GUIDELINES: (tabs 
1310/III , 1313 , 1328, 1329, 1331). 
Dr. Cohen said the proposal had come from Dr. Joseph Fordham of 
Novo Laboratories requesting Section III-B-5 of the NIH 
Guidelines be changed to read: 
"For large-scale (LS) fermentation experiments, 
involving non-pathogenic and non-toxicogenic 
recombinant strains of host organisms having an 
extended history of safe industrial use, the 
appropriate physical containment conditions need to be 
no greater than those for the host organism unmodified 
by recombinant DNA techniques; the IBC can specify 
higher containment if it deems necessary." 
[154] 
Recombinant DNA Research, Volume 13 
